Literature DB >> 12239460

Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma.

Michihiro Koizumi1, Masahiko Onda, Noritake Tanaka, Tomoko Seya, Takeshi Yamada, Yoshiyuki Takahashi.   

Abstract

BACKGROUND: Somatostatin and its analogues have antitumor effects on foregut and midgut neuroendocrine (NE) tumors, but their effect on hindgut NE tumors is unclear. We examined the effect of the somatostatin analogue, octreotide, on human rectal NE carcinoma.
MATERIALS AND METHODS: Expression of somatostatin receptor (sst) on NE carcinoma was examined by immunohistochemical staining. Octreotide was added in cell culture medium in order to investigate antiproliferative effect toward NE carcinoma in vitro. Octreotide was administered for 6 weeks to nude mice xenografted with NE carcinoma. We investigated the effect of octreotide on the tumor histologically. The plasma levels of VEGF and bFGF were measured.
RESULTS: The NE carcinoma and endothelial cells expressed sst. Octreotide induced NE carcinoma to apoptosis in vitro and in vivo. Octreotide-treated tumors had a massive necrotic area (62.7 +/- 19.3% treated vs. 39.7 +/- 20.34% untreated, p < 0.05). Microvessels in the treated tumor were decreased (264.0 +/- 48.2/mm(2) treated vs. 341.4 +/- 56.6/mm(2) untreated, p < 0.05). The plasma levels of VEGF and bFGF were reduced by octreotide.
CONCLUSIONS: Octreotide induces rectal NE carcinoma to apoptosis and inhibits angiogenesis in the tumor. These result in tumor necrosis. Octreotide has an antitumor effect on rectal NE carcinoma. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239460     DOI: 10.1159/000063822

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

Review 1.  Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

Authors:  Joaquin Mateo; John V Heymach; Amado J Zurita
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

Review 2.  Management of acromegaly: is there a role for primary medical therapy?

Authors:  Zachary M Bush; Mary Lee Vance
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

3.  Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro.

Authors:  Manoj Kumar; Zheng-Ren Liu; Laxmi Thapa; Qing Chang; Da-Yu Wang; Ren-Yi Qin
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

4.  Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.

Authors:  Wei-Dong Jia; Ge-Liang Xu; Rong-Nan Xu; Hui-Chuan Sun; Lu Wang; Ji-Hai Yu; Jian Wang; Jian-Sheng Li; Zhi-Ming Zhai; Qiong Xue
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-14       Impact factor: 4.553

Review 5.  Small Bowel and Colorectal Carcinoids.

Authors:  Raphael M Byrne; Rodney F Pommier
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04

Review 6.  Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives.

Authors:  Hui-Chuan Sun; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-03-18       Impact factor: 4.553

7.  Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium.

Authors:  R L Adams; I P Adams; S W Lindow; W Zhong; S L Atkin
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.